Larazotide Acetate

Overview

Larazotide acetate is a synthetic eight-amino-acid peptide studied as a regulator of the intestinal barrier. It is best known as an investigational treatment for celiac disease, where it was developed to be taken orally before meals as an adjunct to a gluten-free diet.

It works at the tight junctions — the sealing structures between the cells that line the gut — and is described as a zonulin-pathway antagonist. The goal is to reduce the excessive intestinal permeability, sometimes referred to as “leaky gut,” that can allow immunogenic gluten fragments to cross the epithelial barrier.

Larazotide became the most clinically advanced non-dietary candidate for celiac disease and was the first such agent to reach a Phase 3 trial. That trial (CeDLara) was discontinued for futility in 2022, and the compound currently has no approved indication.

How it works

In celiac disease, gluten exposure is associated with release of zonulin, a signaling molecule that loosens intestinal tight junctions and increases paracellular permeability. Larazotide is designed to antagonize this pathway, helping the tight-junction proteins stay organized and the barrier stay closed. Preclinical and mechanistic work has linked its activity to effects on myosin light-chain kinase and to redistribution of tight-junction proteins.

Because it is taken orally and appears to act locally within the gut lumen rather than being absorbed systemically, its proposed mechanism is largely confined to the intestinal lining. The full mechanism in humans is still being characterized.

Reported benefits

• Reduction in gluten-induced gastrointestinal symptoms in celiac patients undergoing a gluten challenge (studied in clinical trials)
• Fewer symptomatic days in some patients with persistent symptoms despite a gluten-free diet (reported at a low dose in one trial)
• Support for intestinal barrier function via tight-junction regulation (mechanistic and preclinical data)

These are reported and studied effects, not guaranteed outcomes, and the pivotal Phase 3 trial did not meet its goals.

Considerations & side effects

Across trials, larazotide acetate was generally well tolerated, with adverse-event rates broadly similar to placebo; because it is gut-restricted, systemic exposure is expected to be low. Even so, its clinical benefit was not confirmed in the Phase 3 setting, and it is not an approved therapy for celiac disease or any other condition.

It is not a substitute for a gluten-free diet in celiac disease, nor for evaluation and treatment by a qualified clinician. Material sold outside of clinical trials is unregulated, and purity and identity can vary in the research-chemical market.